Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991;33(3):153-7.
doi: 10.1007/BF01756135.

Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies

D Scholz  1 , M Lubeck, H Loibner, J McDonald-Smith, Y Kimoto, H Koprowski, Z Steplewski
Affiliations

Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies

D Scholz et al. Cancer Immunol Immunother. 1991.

Abstract

The capacity of isotype variants of BR55-2, an anti-tumor monoclonal antibody directed against Y oligosaccharide, to mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in the human system was evaluated using freshly isolated peripheral blood mononuclear cells, lymphocytes, monocytes and complement. The ADCC activities of the BR55-2 IgG3 isotype and its switch variants (IgG1, IgG2b, and IgG2a) with human monocytes were high for all isotypes, whereas the activity of all isotypes was lower with freshly isolated lymphocytes, IgG1 being the least effective. The CDC on the other hand was strong with IgG3, IgG2b and IgG2a and negative with the IgG1 variant. The IgG3 and IgG2a isotypes were selected for further development. Their strong ADCC and CDC activity against mammary carcinoma, colon carcinoma and small-cell lung tumor cell lines was confirmed quantitatively using proteins highly purified from tissue-culture supernatants. Significant variations in ADCC and CDC competence was observed among human donors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Barth A, Waibel R, Stahel RA (1991) Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small cell lung carcinoma (in press) - PubMed
    1. Boyum A. Isolation of leucocytes from human blood. A twophase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest. 1968;21(Suppl.):9. - PubMed
    1. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. 1989;73:651. - PubMed
    1. Freundlich B, Avdalovic NJ. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. Immunol Methods. 1983;62:31. - PubMed
    1. Frodin J, Harmenberg U, Biberfeld P, Christensson B, Lefvert A, Rieger A, Shetye J, Wahren B, Mellstedt H. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma. 1988;7:309. - PubMed

Publication types

MeSH terms

LinkOut - more resources